Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer

Abstract Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally, with KRAS mutations present in approximately 20–25% of cases. The KRAS-G12C mutation, occurring in approximately 14% of lung adenocarcinomas, has emerged as a critical target for precision medic...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongyu Liu, Chao Zhou, Jun Lu, Yuqing Liu, Peichen Zou, Liang Zhu, Huimin Lei, Baohui Han
Format: Article
Language:English
Published: Nature Publishing Group 2025-05-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-025-07687-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items